Arzerra 1000mg Solution for Infusion
Product introduction
Arzerra 1000mg Solution for Infusion is administered subcutaneously (under the skin). Administer the medicine as prescribed and do not skip any doses, as consistency helps maintain its effectiveness. To get the most benefit, follow up with your doctor regularly, stay up to date with vaccinations before starting treatment, and monitor for any signs of infection.
Common side effects of Arzerra 1000mg Solution for Infusion include injection-site reactions such as redness, swelling, or pain, as well as flu-like symptoms like fever, headache, chills, and fatigue, especially after the first doses. These symptoms usually improve with time. Some people may experience upper respiratory infections or urinary tract infections. Staying hydrated and practicing good hygiene can help reduce the risk. If side effects become severe or do not go away, consult your doctor for guidance.
Since Arzerra 1000mg Solution for Infusion lowers certain immune cells, it can increase the risk of infections, including serious ones like hepatitis B reactivation or upper respiratory infections. Before starting treatment, your doctor may check for infections and ensure your vaccinations are up-to-date. Avoid live vaccines while on treatment with Arzerra 1000mg Solution for Infusion, as they may not be safe. If you develop signs of infection, such as a persistent fever, sore throat, or unusual tiredness, seek medical advice promptly. People with a weakened immune system or a history of hepatitis B should discuss risks with their doctor before starting Arzerra 1000mg Solution for Infusion.
Pregnant or breastfeeding women should consult their doctor before using Arzerra 1000mg Solution for Infusion, as it may harm the baby. Both men and women should use effective contraception during treatment to prevent pregnancy. Arzerra 1000mg Solution for Infusion is a strong medication, so always follow your doctor's advice and report any concerns promptly to ensure the best results while minimizing risks.
Uses of Arzerra Solution for Infusion
- Treatment of Relapsing forms of multiple sclerosis (MS)
Benefits of Arzerra Solution for Infusion
In Treatment of Relapsing forms of multiple sclerosis (MS)
Side effects of Arzerra Solution for Infusion
Common side effects of Arzerra
- Headache
- Fever
- Muscle pain
- Chills
- Tiredness
- Injection site reactions (pain, swelling, redness)
- Upper respiratory tract infection
- Urinary tract infection
How to use Arzerra Solution for Infusion
How Arzerra Solution for Infusion works
Safety advice
What if you forget to take Arzerra Solution for Infusion?
All substitutes
Quick tips
- Administer Arzerra 1000mg Solution for Infusion as prescribed to maintain effectiveness. Set reminders if needed.
- Report any signs of infection, such as fever, cough, or sore throat, to your doctor.
- Get necessary vaccines at least 4 weeks before starting treatment, and avoid live vaccines during treatment.
- Use birth control during treatment and for at least 6 months after stopping.
- Drink plenty of water and rest to ease flu-like side effects.
- Follow up regularly with your doctor to monitor progress and manage side effects early.
Fact Box
Interaction with drugs
Patient concerns
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1747-48.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 1011.